



*The Raydiant team (from left to right): Terry Han, chief scientific officer; Neil Ray, MD, chief medical officer; and Nicole Hlava, MD, chief executive officer*

### **Fogarty Institute adds four new startups; two companies graduate**

Following a very competitive application process, the Fogarty Institute is excited to welcome four new startups to its incubator program: Healyx, palmm, Radial Medical and Raydiant Oximetry. The companies were selected based on their proven experience in the space, potential to develop innovative methods to serve unmet healthcare needs and interest in advancing our mission of transforming the industry.

The new startups join the Institute as two other companies, [nVision Medical](#) and [InPress Technologies](#), graduate. Both companies have received funding and shown that their technologies have evolved sufficiently to allow the startups to move to their own facilities and operate independently. Seven companies have now successfully graduated since the Institute's inception nearly 10 years ago.

"The application process was rigorous, and we are delighted to welcome these qualified companies, whose unique focuses support our goal to address a broad spectrum of patient needs," said Andrew Cleeland, CEO of the Fogarty Institute. "We look forward to mentoring and educating them to help them thrive and make an impact – not only to solve specific healthcare needs, but to become financially successful entities that will offer a sustained impact. We believe they will be a strong addition to our growing roster of successful graduate companies."



*The Radial Medical team in front of the R&D garage workshop where they started. From left to right: James Wall, MD; Gil Laroya; Eric Johnson; and Conrad Salinas.*

### **About the New Startups**

- **Healyx** is developing an innovative, cost-effective solution aimed at helping doctors in low-income countries successfully treat patients with severe wounds, with a device that improves on the highly regarded method of Negative Pressure Wound Therapy (NPWT).

In resource-constrained countries, non-healing wounds such as burns, trauma wounds, diabetic ulcers and pressure sores compound overcrowding in hospitals and place a significant expense on patients, driven by daily gauze dressing changes and hospital charges. The problem is immense: The incidence of open wounds exceeds 110 million patients worldwide and is growing due to an aging global population and increasing rates of diseases that cause chronic wounds.

Healyx was launched in 2015 as part of one of Stanford's social innovation programs, [Design for Extreme Affordability](#). The leadership team consists of co-founders Cam Hutton, CEO, and Madeline Sides, product lead.



*Justin Huelman and Véronique Peiffer, co-founders of palmm*

- **palmm** is developing a simple, at-home treatment for hyperhidrosis, also known as excessive sweating. Fifteen million Americans suffer from this condition, which can dramatically affect quality of life in both social and professional situations.

While hyperhidrosis can affect several locations on the body, patients find the condition the most bothersome on the hands, which is palmm's initial focus. Current treatment options (including antiperspirants, iontophoresis, botox injections and cardiothoracic surgery) are all either ineffective, inconvenient, costly or invasive, leaving an important clinical need unmet.

palmm was founded by Justin Huelman and Véronique Peiffer, both former Innovation Fellows at Stanford University's Byers Center for Biodesign.

- **Radial Medical** is an early-stage company developing innovative therapies in the consumer and medical fields.

Founded in 2016 by Eric Johnson and Dr. James Wall, the team has over 75 years of combined experience in developing and commercializing medical devices. Most recently, Eric founded Crux Biomedical, a company which developed an inferior vena cava filter to treat pulmonary embolisms that was acquired by Volcano Corporation. Dr. Wall founded Insite Medical Technologies, a company that commercialized a proprietary medical device to provide safe and accurate delivery of epidural anesthesia.

- **Raydiant Oximetry** is developing a novel, non-invasive, medical device to determine fetal oxygen levels during the third trimester of pregnancy and labor. Inaccuracies in the current system of monitoring fetal health during labor have led to almost one in 10 pregnancies requiring an unanticipated Cesarean section.

Although sometimes necessary, C-sections can have multiple negative effects to the health of both mothers and babies and increase healthcare and insurance costs. With knowledge of the baby's oxygen level, Raydiant's device can keep women and babies safer and healthier after childbirth.

The team consists of Nicole Hlava, MD, chief executive officer; Neil Ray, MD, chief medical officer; Terry Han, Ph.D., chief scientific officer; and Heidi Bell, MD, medical director.